Nima Amjadi, MD
Cardiovascular Disease · Dripping Springs, TXNPI 1114974011
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 1,092 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $6,728 and has fallen 72.2% since, to $1,868 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,092 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$5K
- Johnson & Johnson$2K
- Amgen$2K
- Novartis$2K
- Abiomed$1K
- Medtronic$1K
- plus $13K from 54 others
Across 5 payments — averaging $9771.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$39K
- Boehringer Ingelheim$10K
What the payments were for
- Speaking & faculty fees$2,1008%
- Travel & lodging$3761%
- Food & beverage$24,43190%
- Education$250%
- Entertainment$760%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$568
- LUTONIX$554
- EKOSONIC$376
- Indigo System$376
- COBALT DR MRI SURESCAN$280
- (9520) IGT Devices Undivided$274
- FLOWTRIEVER CATHETER, S$268
- CT THROMBECTOMY SYSTEM KIT$268
- CoreValve Evolut$246
- VENOVO$237
- AMPLATZER Occluders$151
- Grafts$150
- RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM$143
- Azure$137
- Torus Stent Graft System$123
- ENDOCROSS Device$123
- PRALUENT$120
- HawkOne$113
- Impella$111
- MYNX CONTROL$103
How this compares
$27,008 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 330 | $390,184 |
| XareltoRivaroxaban | 244 | $308,226 |
| Repatha SureclickEvolocumab | 107 | $127,876 |
| OzempicSemaglutide | 74 | $96,985 |
| EntrestoSacubitril/Valsartan | 84 | $95,796 |
| MounjaroTirzepatide | 42 | $44,417 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 51 | $26,267 |
| FarxigaDapagliflozin Propanediol | 35 | $25,728 |
| VascepaIcosapent Ethyl | 28 | $24,381 |
| Nebivolol Hcl | 573 | $24,354 |
| BrilintaTicagrelor | 21 | $13,432 |
| Rosuvastatin Calcium | 1,014 | $12,864 |
| EdarbiAzilsartan Medoxomil | 21 | $10,265 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 371 | $10,188 |
| Metoprolol Succinate | 350 | $5,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $660 | $390,184330 claims |
| Johnson & JohnsonXarelto | $2,399 | $308,226244 claims |
| Novo NordiskOzempic | $712 | $96,98574 claims |
| NovartisEntresto | $1,744 | $95,79684 claims |
| Lilly USA, LLCMounjaro | $137 | $44,41742 claims |
| AstraZenecaFarxiga, Brilinta | $907 | $39,16056 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $265 | $36,53172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Dripping Springs
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.